Adverum Biotechnologies - Stock Price History | ADVM

Historical daily share price chart and data for Adverum Biotechnologies since 2021 adjusted for splits. The latest closing stock price for Adverum Biotechnologies as of October 22, 2021 is 1.95.
  • The all-time high Adverum Biotechnologies stock closing price was 25.64 on June 23, 2020.
  • The Adverum Biotechnologies 52-week high stock price is 14.79, which is 658.5% above the current share price.
  • The Adverum Biotechnologies 52-week low stock price is 1.92, which is 1.5% below the current share price.
  • The average Adverum Biotechnologies stock price for the last 52 weeks is 7.44.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Adverum Biotechnologies Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 14.1853 11.7400 25.6400 7.9800 10.8400 -5.90%
2019 8.1478 3.4100 15.8900 3.0300 11.5200 265.71%
2018 5.4768 3.6500 7.9500 2.8700 3.1500 -10.00%
2017 2.9114 2.9500 3.9500 2.4500 3.5000 20.69%
2016 3.6034 3.8800 4.7600 2.8000 2.9000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.191B $0.000B
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum?s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76